back to top
- Improving Outcomes in High-Risk MDS and CMML: Which Needle(s) to Use Remain Lost in the HaystackOctober 10, 2017 | November-December 2017, Volume 14, Issue 6
Dr. Keel looks at a study that considers azacitidine-based combination chemotherapy as therapy for a subset of high-risk MDS patients with chronic myelomonocytic leukemia.
- Things Are Not Always What They Seem: Marrow Failure From a Hematopoietic Cell-Extrinsic Mechanism Due to Germline Mutations in ThrombopoietinAugust 14, 2017 | September-October 2017, Volume 14, Issue 5
Dr. Keel reviews a study that shows that patients with germline THPO mutations resulting in marrow failure do not benefit from stem cell transplantation, but instead respond to thrombopoietin mimetic therapy.
- Are We Recruiting an Army for Magneto? Optimizing Iron Utilization in HemodialysisJuly 01, 2017 | July-August 2017, Volume 14, Issue 4
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
- Precision Medicine at Work: Genetic Profiling to Guide Stem-Cell Transplantation in Myelodysplastic SyndromesMay 01, 2017 | May-June 2017, Volume 14, Issue 3
Dr. Keel reviews the use of genetic profiling to guide stem-cell transplantation in myelodysplastic syndromes.
- Where and When Did it All Go Wrong? Deciphering the Molecular Pathophysiology of Disease Progression in MDSMarch 01, 2017 | March-April 2017, Volume 14, Issue 2
Dr. Keel reviews a study that looks at how distinct molecular events affect MDS disease progression, suggesting that screening for specific mutations might be useful to predict clinical outcome.
- HIT Me With Your Best Shot: Promising Advances in HIT Prevention and TreatmentJanuary 01, 2017 | January-February 2017, Volume 14, Issue 1
Dr. Keel reviews promising advances during 2016 in HIT prevention and treatment, while mentioning the need for further trials to confirm the safety and efficacy of existing anticoagulants.
- If We Could Turn Back Time: Danazol Preserves Telomere Length in Patients With Telomere DysfunctionOctober 28, 2016 | November-December 2016, Volume 13, Issue 6
Dr. Keel discusses studies carried out to determine the efficacy of androgens to treat or prevent other disease manifestations associated with short telomere syndromes.
- CML No Longer Means Early DeathAugust 12, 2016 | September-October 2016, Volume 13, Issue 5
Dr. Keel reviews a study that looks at an increase in life expectancy for chronic myeloid leukemia (CML) patients as CML treatment has changed dramatically over time.
- Is Less More in Therapy for High-Risk MDS in the Elderly?June 14, 2016 | July-August 2016, Volume 13, Issue 4
Dr. Keel talks about a study that compares risks and benefits of alloHCT in older patients with higher-risk myelodysplastic syndromes.
- Elegant Biology: Glycine- and Folate-correctable SLC25A38-mutated Sideroblastic AnemiaApril 07, 2016 | May-June 2016, Volume 13, Issue 3
Dr. Keel covers an approach to treating congenital sideroblastic anemia caused by SLC25A38 deficiency with glycine and folic acid supplementation.
Dr. Keel is associate professor of medicine in the division of hematology at the University of Washington School of Medicine. Her clinical interests include benign red blood cell disorders, iron metabolism (including iron deficiency and hereditary hemochromatosis), acquired aplastic anemia, congenital marrow failure syndromes, and the transition of care between pediatric and adult hematologists. Her research interests include normal and ineffective erythropoiesis, systemic and cellular iron homeostasis, and the clinical presentation and molecular underpinnings of inherited marrow failure.
University of Washington School of Medicine